J. Paul Hamilton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
J. Paul Hamilton has a total of 589 co-authors. Here are the top co-authors by number of shared publications:
Matthew D. Sacchet
6 shared publicationsRobin Kämpe
6 shared publications- Elisabeth Paul
Center for Social and Affective Neuroscience, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
5 shared publications - Ian H. Gotlib
Department of Psychology, Stanford University, Stanford, USA
5 shared publications Markus Heilig
5 shared publications- Irene Perini
Center for Social and Affective Neuroscience, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
4 shared publications
Latest Publications
- 15 June 2026
- Published by Springer Nature in Nature Mental Health
- Vol. 4 (7) , 1175-1186
Vertex-wise cortical abnormalities in major depressive disorder from 64 cohorts from the DIRECT and ENIGMA MDD consortia
- 15 June 2026
- Published by Springer Nature in Nature Mental Health
- Vol. 4 (7) , 1175-1186
Vertex-wise cortical abnormalities in major depressive disorder from 64 cohorts from the DIRECT and ENIGMA MDD consortia
- 25 March 2026
- Published by Elsevier in Biological Psychiatry
- Vol. 99 (8) , 610-611
Connections Between Connections in the Brain Offer Novel Insights Into Major Depressive Disorder
- 25 March 2026
- Published by Elsevier in Biological Psychiatry
- Vol. 99 (8) , 610-611
Connections Between Connections in the Brain Offer Novel Insights Into Major Depressive Disorder
- Open Access
- 12 December 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (12) , 1323
Innovations in Meta-Analytic and Computational Methods in the Neuroscientific Investigation of Psychiatric and Neurological Disorders
Recent advancements in neuroimaging and genetics have generated a rapid proliferation of primary studies in these fields, leading to the development and application of meta-analytic methods, which have contributed substantially to our understanding of psychiatric and neurological disorders. The current narrative review discusses four such innovations and applications in meta-analytic techniques and how they have advanced our understanding of clinical conditions: (1) multilevel kernel density analysis (MKDA) of functional magnetic resonance imaging (fMRI) studies, (2) meta-analyses of positron emission tomography (PET) imaging of neuroinflammation, (3) Enhancing Neuroimaging Genetics through Meta-Analysis (ENIGMA) Consortium neuroimaging protocols, and (4) meta-genome-wide association studies (Meta-GWASs) and polygenic risk scores (PRSs). These meta-analytic methods have contributed substantially to our understanding of psychiatric and neurological disorders by refining robust neural models, identifying transdiagnostic and disease-specific biomarkers of inflammation, uncovering numerous genetic risk variants with improved prediction models, and underscoring the polygenic and pleiotropic architecture of these conditions. Future research should continue to develop techniques for harmonizing multimodal data analysis, pursue both biomarker- and mechanism-driven approaches to discovery, and leverage biological discoveries to advance development of precision treatments and diagnostic frameworks.
- 12 December 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (12) , 1323
Open AccessInnovations in Meta-Analytic and Computational Methods in the Neuroscientific Investigation of Psychiatric and Neurological Disorders
Recent advancements in neuroimaging and genetics have generated a rapid proliferation of primary studies in these fields, leading to the development and application of meta-analytic methods, which have contributed substantially to our understanding of psychiatric and neurological disorders. The current narrative review discusses four such innovations and applications in meta-analytic techniques and how they have advanced our understanding of clinical conditions: (1) multilevel kernel density analysis (MKDA) of functional magnetic resonance imaging (fMRI) studies, (2) meta-analyses of positron emission tomography (PET) imaging of neuroinflammation, (3) Enhancing Neuroimaging Genetics through Meta-Analysis (ENIGMA) Consortium neuroimaging protocols, and (4) meta-genome-wide association studies (Meta-GWASs) and polygenic risk scores (PRSs). These meta-analytic methods have contributed substantially to our understanding of psychiatric and neurological disorders by refining robust neural models, identifying transdiagnostic and disease-specific biomarkers of inflammation, uncovering numerous genetic risk variants with improved prediction models, and underscoring the polygenic and pleiotropic architecture of these conditions. Future research should continue to develop techniques for harmonizing multimodal data analysis, pursue both biomarker- and mechanism-driven approaches to discovery, and leverage biological discoveries to advance development of precision treatments and diagnostic frameworks.
- Open Access
- 28 November 2025
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 50
Immune and metabolic disturbance as a function of genetic risk and phase of illness in major depression
- 28 November 2025
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 50
Open AccessImmune and metabolic disturbance as a function of genetic risk and phase of illness in major depression
- Open Access
- 26 February 2024
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 49 (6) , 1042-1049
Ghrelin decreases sensitivity to negative feedback and increases prediction-error related caudate activity in humans, a randomized controlled trial
The stomach-derived hormone ghrelin plays not only a role in feeding, starvation, and survival, but it has been suggested to also be involved in the stress response, in neuropsychiatric conditions, and in alcohol and drug use disorders. Mechanisms related to reward processing might mediate ghrelin’s broader effects on complex behaviors, as indicated by animal studies and mostly correlative human studies. Here, using a within-subject double-blind placebo-controlled design with intravenous ghrelin infusion in healthy volunteers (n = 30), we tested whether ghrelin alters sensitivity to reward and punishment in a reward learning task. Parameters were derived from a computational model of participants’ task behavior. The reversal learning task with monetary rewards was performed during functional brain imaging to investigate ghrelin effects on brain signals related to reward prediction errors. Compared to placebo, ghrelin decreased punishment sensitivity (t = −2.448, p = 0.021), while reward sensitivity was unaltered (t = 0.8, p = 0.43). We furthermore found increased prediction-error related activity in the dorsal striatum during ghrelin administration (region of interest analysis: t-values ≥ 4.21, p-values ≤ 0.044). Our results support a role for ghrelin in reward processing that extends beyond food-related rewards. Reduced sensitivity to negative outcomes and increased processing of prediction errors may be beneficial for food foraging when hungry but could also relate to increased risk taking and impulsivity in the broader context of addictive behaviors.
- 26 February 2024
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 49 (6) , 1042-1049
Open AccessGhrelin decreases sensitivity to negative feedback and increases prediction-error related caudate activity in humans, a randomized controlled trial
The stomach-derived hormone ghrelin plays not only a role in feeding, starvation, and survival, but it has been suggested to also be involved in the stress response, in neuropsychiatric conditions, and in alcohol and drug use disorders. Mechanisms related to reward processing might mediate ghrelin’s broader effects on complex behaviors, as indicated by animal studies and mostly correlative human studies. Here, using a within-subject double-blind placebo-controlled design with intravenous ghrelin infusion in healthy volunteers (n = 30), we tested whether ghrelin alters sensitivity to reward and punishment in a reward learning task. Parameters were derived from a computational model of participants’ task behavior. The reversal learning task with monetary rewards was performed during functional brain imaging to investigate ghrelin effects on brain signals related to reward prediction errors. Compared to placebo, ghrelin decreased punishment sensitivity (t = −2.448, p = 0.021), while reward sensitivity was unaltered (t = 0.8, p = 0.43). We furthermore found increased prediction-error related activity in the dorsal striatum during ghrelin administration (region of interest analysis: t-values ≥ 4.21, p-values ≤ 0.044). Our results support a role for ghrelin in reward processing that extends beyond food-related rewards. Reduced sensitivity to negative outcomes and increased processing of prediction errors may be beneficial for food foraging when hungry but could also relate to increased risk taking and impulsivity in the broader context of addictive behaviors.
- Open Access
- 11 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-18
Multi-site benchmark classification of major depressive disorder using machine learning on cortical and subcortical measures
Machine learning (ML) techniques have gained popularity in the neuroimaging field due to their potential for classifying neuropsychiatric disorders. However, the diagnostic predictive power of the existing algorithms has been limited by small sample sizes, lack of representativeness, data leakage, and/or overfitting. Here, we overcome these limitations with the largest multi-site sample size to date (N = 5365) to provide a generalizable ML classification benchmark of major depressive disorder (MDD) using shallow linear and non-linear models. Leveraging brain measures from standardized ENIGMA analysis pipelines in FreeSurfer, we were able to classify MDD versus healthy controls (HC) with a balanced accuracy of around 62%. But after harmonizing the data, e.g., using ComBat, the balanced accuracy dropped to approximately 52%. Accuracy results close to random chance levels were also observed in stratified groups according to age of onset, antidepressant use, number of episodes and sex. Future studies incorporating higher dimensional brain imaging/phenotype features, and/or using more advanced machine and deep learning methods may yield more encouraging prospects.
- 11 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-18
Open AccessMulti-site benchmark classification of major depressive disorder using machine learning on cortical and subcortical measures
Machine learning (ML) techniques have gained popularity in the neuroimaging field due to their potential for classifying neuropsychiatric disorders. However, the diagnostic predictive power of the existing algorithms has been limited by small sample sizes, lack of representativeness, data leakage, and/or overfitting. Here, we overcome these limitations with the largest multi-site sample size to date (N = 5365) to provide a generalizable ML classification benchmark of major depressive disorder (MDD) using shallow linear and non-linear models. Leveraging brain measures from standardized ENIGMA analysis pipelines in FreeSurfer, we were able to classify MDD versus healthy controls (HC) with a balanced accuracy of around 62%. But after harmonizing the data, e.g., using ComBat, the balanced accuracy dropped to approximately 52%. Accuracy results close to random chance levels were also observed in stratified groups according to age of onset, antidepressant use, number of episodes and sex. Future studies incorporating higher dimensional brain imaging/phenotype features, and/or using more advanced machine and deep learning methods may yield more encouraging prospects.
- Open Access
- 23 December 2023
- Published by Elsevier in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
- Vol. 9 (4) , 437-446
Contributions of Polygenic Risk and Disease Status to Gray Matter Abnormalities in Major Depression
- 23 December 2023
- Published by Elsevier in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
- Vol. 9 (4) , 437-446
Open AccessContributions of Polygenic Risk and Disease Status to Gray Matter Abnormalities in Major Depression
- Open Access
- 15 September 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (9) , 1329
Efficient Brain Age Prediction from 3D MRI Volumes Using 2D Projections
Using 3D CNNs on high-resolution medical volumes is very computationally demanding, especially for large datasets like UK Biobank, which aims to scan 100,000 subjects. Here, we demonstrate that using 2D CNNs on a few 2D projections (representing mean and standard deviation across axial, sagittal and coronal slices) of 3D volumes leads to reasonable test accuracy (mean absolute error of about 3.5 years) when predicting age from brain volumes. Using our approach, one training epoch with 20,324 subjects takes 20–50 s using a single GPU, which is two orders of magnitude faster than a small 3D CNN. This speedup is explained by the fact that 3D brain volumes contain a lot of redundant information, which can be efficiently compressed using 2D projections. These results are important for researchers who do not have access to expensive GPU hardware for 3D CNNs.
- 15 September 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (9) , 1329
Open AccessEfficient Brain Age Prediction from 3D MRI Volumes Using 2D Projections
Using 3D CNNs on high-resolution medical volumes is very computationally demanding, especially for large datasets like UK Biobank, which aims to scan 100,000 subjects. Here, we demonstrate that using 2D CNNs on a few 2D projections (representing mean and standard deviation across axial, sagittal and coronal slices) of 3D volumes leads to reasonable test accuracy (mean absolute error of about 3.5 years) when predicting age from brain volumes. Using our approach, one training epoch with 20,324 subjects takes 20–50 s using a single GPU, which is two orders of magnitude faster than a small 3D CNN. This speedup is explained by the fact that 3D brain volumes contain a lot of redundant information, which can be efficiently compressed using 2D projections. These results are important for researchers who do not have access to expensive GPU hardware for 3D CNNs.
- Open Access
- 15 June 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (12)
A randomized controlled experimental medicine study of ghrelin in value-based decision making
BACKGROUND. The stomach-derived hormone ghrelin stimulates appetite, but the ghrelin receptor is also expressed in brain circuits involved in motivation and reward. We examined ghrelin effects on decision making beyond food or drug reward using monetary rewards. METHODS. Thirty participants (50% women and 50% men) underwent 2 fMRI scans while receiving i.v. ghrelin or saline in a randomized counterbalanced order. RESULTS. Striatal representations of reward anticipation were unaffected by ghrelin, while activity during anticipation of losses was attenuated. Temporal discounting rates of monetary reward were lower overall in the ghrelin condition, an effect driven by women. Discounting rates were inversely correlated with neural activity in a large cluster within the left parietal lobule that included the angular gyrus. Activity in an overlapping cluster was related to behavioral choices and was suppressed by ghrelin. CONCLUSION. This is, to our knowledge, the first human study to extend the understanding of ghrelin’s significance beyond the canonical feeding domain or in relation to addictive substances. Contrary to our hypothesis, we found that ghrelin did not affect sensitivity to monetary reward anticipation, but rather resulted in attenuated loss aversion and lower discounting rates for these rewards. Ghrelin may cause a motivational shift toward caloric reward rather than globally promoting the value of reward. TRIAL REGISTRATION. EudraCT 2018-004829-82. FUNDING. Swedish Research Council (2013-07434), Marcus and Marianne Wallenberg foundation (2014.0187) and National Institute on Drug Abuse/National Institute on Alcohol Abuse and Alcoholism Intramural Research Program.
- 15 June 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (12)
Open AccessA randomized controlled experimental medicine study of ghrelin in value-based decision making
BACKGROUND. The stomach-derived hormone ghrelin stimulates appetite, but the ghrelin receptor is also expressed in brain circuits involved in motivation and reward. We examined ghrelin effects on decision making beyond food or drug reward using monetary rewards. METHODS. Thirty participants (50% women and 50% men) underwent 2 fMRI scans while receiving i.v. ghrelin or saline in a randomized counterbalanced order. RESULTS. Striatal representations of reward anticipation were unaffected by ghrelin, while activity during anticipation of losses was attenuated. Temporal discounting rates of monetary reward were lower overall in the ghrelin condition, an effect driven by women. Discounting rates were inversely correlated with neural activity in a large cluster within the left parietal lobule that included the angular gyrus. Activity in an overlapping cluster was related to behavioral choices and was suppressed by ghrelin. CONCLUSION. This is, to our knowledge, the first human study to extend the understanding of ghrelin’s significance beyond the canonical feeding domain or in relation to addictive substances. Contrary to our hypothesis, we found that ghrelin did not affect sensitivity to monetary reward anticipation, but rather resulted in attenuated loss aversion and lower discounting rates for these rewards. Ghrelin may cause a motivational shift toward caloric reward rather than globally promoting the value of reward. TRIAL REGISTRATION. EudraCT 2018-004829-82. FUNDING. Swedish Research Council (2013-07434), Marcus and Marianne Wallenberg foundation (2014.0187) and National Institute on Drug Abuse/National Institute on Alcohol Abuse and Alcoholism Intramural Research Program.
- Open Access
- 19 May 2023
- Published by Springer Nature in Translational Psychiatry
- Vol. 13 (1) , 1-8
Towards a multilevel model of major depression: genes, immuno-metabolic function, and cortico-striatal signaling
Biological assay and imaging techniques have made visible a great deal of the machinery of mental illness. Over fifty years of investigation of mood disorders using these technologies has identified several biological regularities in these disorders. Here we present a narrative connecting genetic, cytokine, neurotransmitter, and neural-systems-level findings in major depressive disorder (MDD). Specifically, we connect recent genome-wide findings in MDD to metabolic and immunological disturbance in this disorder and then detail links between immunological abnormalities and dopaminergic signaling within cortico-striatal circuitry. Following this, we discuss implications of reduced dopaminergic tone for cortico-striatal signal conduction in MDD. Finally, we specify some of the flaws in the current model and propose ways forward for advancing multilevel formulations of MDD most efficiently.
- 19 May 2023
- Published by Springer Nature in Translational Psychiatry
- Vol. 13 (1) , 1-8
Open AccessTowards a multilevel model of major depression: genes, immuno-metabolic function, and cortico-striatal signaling
Biological assay and imaging techniques have made visible a great deal of the machinery of mental illness. Over fifty years of investigation of mood disorders using these technologies has identified several biological regularities in these disorders. Here we present a narrative connecting genetic, cytokine, neurotransmitter, and neural-systems-level findings in major depressive disorder (MDD). Specifically, we connect recent genome-wide findings in MDD to metabolic and immunological disturbance in this disorder and then detail links between immunological abnormalities and dopaminergic signaling within cortico-striatal circuitry. Following this, we discuss implications of reduced dopaminergic tone for cortico-striatal signal conduction in MDD. Finally, we specify some of the flaws in the current model and propose ways forward for advancing multilevel formulations of MDD most efficiently.